Novartis has agreed to buy Myricx Bio to improve its cancer treatment portfolio, while members of the U.S. Congress have emphasized their commitment to maintaining diversity standards in clinical research.

諾華已同意收購 Myricx Bio 以完善其癌症治療產品組合，同時美國國會議員強調將致力維持臨床研究中的多樣性標準。

Novartis is acquiring the London-based company Myricx Bio for an initial payment of $1.1 billion, with an additional $400 million possible depending on future goals. The deal is expected to finish in late 2026 after receiving regulatory approval. This acquisition allows Novartis to use a new antibody-drug conjugate (ADC) platform. Novartis emphasized that this technology uses a different mechanism than traditional inhibitors, which should help prevent drug resistance and make treatments more effective for various solid tumors.

諾華將以 11 億美元的初始付款收購總部位於倫敦的 Myricx Bio，並根據未來目標可能追加 4 億美元。該交易預計在 2026 年底獲得監管部門批准後完成。此次收購使諾華能夠使用一個新的抗體藥物偶聯物 (ADC) 平台。諾華強調，這項技術使用的機制與傳統抑制劑不同，應有助於防止耐藥性，並提高針對各種實體腫瘤的治療效果。

At the same time, there is a new legislative effort in the U.S. House of Representatives to protect diversity in clinical trials. Although there have been political challenges to diversity and inclusion policies, the Republican-led House passed an FDA funding bill. This bill includes a report stating that the FDA must continue to require pharmaceutical companies to provide detailed plans to ensure their clinical trials include a diverse group of participants.

與此同時，美國眾議院正透過新的立法努力來保護臨床試驗的多樣性。儘管多樣性與包容性政策面臨政治挑戰，但由共和黨領導的眾議院通過了一項 FDA 撥款法案。該法案包含一份報告，指出 FDA 必須繼續要求製藥公司提供詳細計劃，以確保其臨床試驗包含多樣化的參與者群體。

In summary, Novartis is growing its cancer research capabilities by purchasing Myricx Bio, while the U.S. House has confirmed its support for FDA rules on clinical trial diversity.

總結來說，諾華透過收購 Myricx Bio 擴展其癌症研究能力，而美國眾議院則確認支持 FDA 關於臨床試驗多樣性的規定。